Compare
Harvard Apparatus Regenerative Technology, Inc. vs Co-Diagnostics, Inc. vs Catheter Precision, Inc. vs Sintx Technologies, Inc.
| Latest fiscal year | Harvard Apparatus Regenerative Technology, Inc. HRGN | Co-Diagnostics, Inc. CODX | Catheter Precision, Inc. VTAK | Sintx Technologies, Inc. SINT |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $704.0K | $622.5K | $819.0K | $1.02M |
| Revenue growth (YoY) | +63.7% | -84.1% | +95.0% | -64.7% |
| Gross margin | n/a | 64.3% | 92.3% | 45.3% |
| Operating margin | -982.2% | n/m | n/m | n/m |
| Net margin | -975.7% | n/m | n/m | n/m |
| Net income | -$6.87M | -$46.90M | -$17.18M | -$10.36M |
| EPS (Diluted) | n/a | -$35.25 | n/a | -$6.16 |
| Operating cash flow | -$3.83M | -$29.14M | -$8.30M | -$8.57M |
| Free cash flow | n/a | -$29.84M | -$8.31M | -$8.76M |
| Cash & equivalents | $1.35M | $11.88M | $88.0K | $4.14M |
| Total assets | $2.68M | $24.74M | $15.86M | $9.51M |
| Total liabilities | $1.62M | $4.11M | $9.21M | $6.58M |
| Shareholders' equity | $1.06M | $20.63M | $7.05M | $2.93M |
| Return on year-end equity | -649.9% | -227.3% | -243.6% | -353.8% |
| Shares outstanding | 17.58M | 2.10M | 1.74M | 3.97M |
Revenue, most recent five fiscal years
| Fiscal year | Harvard Apparatus Regenerative Technology, Inc. | Co-Diagnostics, Inc. | Catheter Precision, Inc. | Sintx Technologies, Inc. |
|---|---|---|---|---|
| Latest | $704.0K Ended 2025-12-31 | $622.5K Ended 2025-12-31 | $819.0K Ended 2025-12-31 | $1.02M Ended 2025-12-31 |
| 1 year earlier | $430.0K Ended 2024-12-31 | $3.92M Ended 2024-12-31 | $420.0K Ended 2024-12-31 | $2.89M Ended 2024-12-31 |
| 2 years earlier | $103.0K Ended 2023-12-31 | $6.81M Ended 2023-12-31 | $442.0K Ended 2023-12-31 | $2.63M Ended 2023-12-31 |
| 3 years earlier | n/a | $34.22M Ended 2022-12-31 | $14.0K Ended 2022-12-31 | $1.56M Ended 2022-12-31 |
| 4 years earlier | n/a | $97.89M Ended 2021-12-31 | $22.0K Ended 2021-12-31 | $606.0K Ended 2021-12-31 |